跳到正文
原文
Endpoints News 生物医药· Max Gelman·· 2026-10-12AI 评分60

Bristol Myers Squibb 两项 III 期研究成功,涉及 RayzeBio 药物

Bristol Myers reveals a pair of Phase 3 wins for fibrosis, RayzeBio drugs

AI 导读

Bristol Myers Squibb 周一报告两项 III 期研究成功,其中一项涉及近期出现安全性问题的在研药物,涉及 RayzeBio 药物。原文正文未提供药名、适应症、具体终点或数值。

正文

Bris­tol My­ers Squibb re­port­ed two Phase 3 suc­cess­es on Mon­day morn­ing, in­clud­ing for an ex­per­i­men­tal drug that re­cent­ly ran in­to safe­ty is­sues.

A tri­al test­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news